Piper Sandler raised the firm’s price target on Amgen (AMGN) to $381 from $342 and keeps an Overweight rating on the shares. The firm notes monthly third-party prescription data for October 2025 became available recently, and this piece highlights Rx data and trends for a number of key Amgen products. Looking at Repatha and Tezspire more specifically, Piper continues to believe that visibility into aggressive volume growth for both products is high.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN: